Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000115

Director sold 18,000 shares at an average $104.93 ($1,888,749)

  • Director acquired 18,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

BALL KRISTINE M · Director

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-11-12 Exercise or conversion : show line 1 in the form 10b5-1 +18,000 $6.84 $123,120 18,000 D
2026-11-12 Sale : show line 2 in the form 10b5-1 −1,196 $102.10 $122,108 16,804 D
2026-11-12 Sale : show line 3 in the form 10b5-1 −1,300 $103.09 $134,021 15,504 D
2026-11-12 Sale : show line 4 in the form 10b5-1 −2,039 $104.16 $212,387 13,465 D
2026-11-12 Sale : show line 5 in the form 10b5-1 −10,765 $105.31 $1,133,706 2,700 D
2026-11-12 Sale : show line 6 in the form 10b5-1 −2,500 $106.05 $265,130 200 D
2026-11-12 Sale : show line 7 in the form 10b5-1 −200 $106.99 $21,397 0 D
Open-market sales · 18,000 sh · avg $104.93 · $1,888,749

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-11-12 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) −18,000 53,426 D
Loading xslF345X06/form4.xml…